Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral HTMC0435 plus temozolomide in advanced solid tumors
CTR20233204Phase 2Active
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HTMC0435 in Nonhematologic neoplasms, sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.. Started Oct 2023; status: active.
02
Drugs
HTMC0435
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20233204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233204.